Integral Ad Science

Business

Twist Bioscience Powers Ahead: Q1 2026 Revenue Jumps 17%, Fueled by AI-Driven Discovery Boom

Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.

Feb 2, 2026

Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Jan 31, 2026

Business

IAS Bolsters Board with Ad-Tech Heavyweights, Signaling Streaming Ambitions

Integral Ad Science appoints Horizon Media's Bob Lord and Amazon's former video ad chief Krishan Bhatia to its board, a move analysts say sharpens its focus on the convergence of streaming, data, and advertising technology.

Feb 2, 2026

Business

Edwards Lifesciences Halts JenaValve Acquisition, Doubles Down on Core Valve Technology

Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.

Feb 2, 2026

Business

Cogent Biosciences Gains Key FDA Designations for Bezuclastinib, Spotlighting GIST Treatment Potential

Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.

Feb 2, 2026

Business

FDA Grants Breakthrough Status to Cogent Biosciences' GIST Combo Therapy, Accelerating Path to Market

Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.

Feb 2, 2026

Business

IDEAYA Biosciences: A Buying Opportunity After the Pullback, or Priced for Perfection?

IDEAYA Biosciences shares have retreated from recent highs, presenting investors with a dilemma. While long-term performance remains strong, its premium valuation and significant net losses raise questions about whether the current price already reflects its promising pipeline.

Feb 2, 2026

Business

Three TSX Venture Penny Stocks Poised for Growth Amid Canada's Steady Rate Environment

As the Bank of Canada signals a hold on interest rates, a backdrop of market stability is emerging. This analysis delves into three Canadian penny stocks—Britannia Life Sciences, ROK Resources, and Vision Lithium—that present distinct risk-reward profiles for investors eyeing the junior markets in early 2026.

Jan 30, 2026

Business

Eli Lilly Commits $3.5 Billion to Pennsylvania, Creating 850 Jobs in Major Life Sciences Push

Pharmaceutical leader Eli Lilly will build a new manufacturing facility in Lehigh County, marking the largest life sciences investment in Pennsylvania history and bolstering U.S. production of next-generation weight-loss drugs.

Jan 30, 2026

Business

Analysts Bullish on Ardelyx Ahead of Q4 Earnings, Citing Blockbuster Potential for Key Drug

Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.

Feb 2, 2026

Business

Jefferies Downgrades Amicus to 'Buy' Amid BioMarin Acquisition, Sees Limited Upside

Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.

Feb 2, 2026

Business

Edwards Lifesciences: Strong Fundamentals Mask Growth Concerns as Stock Slips

Despite a recent 4.7% stock decline, Edwards Lifesciences (NYSE: EW) boasts a robust 13% Return on Equity, outperforming its industry. Yet, its modest 4.6% five-year growth rate raises questions about future potential and market valuation.

Feb 2, 2026

World

Nigeria Files 57 Terrorism Charges Over 2025 Yelwata Massacre That Left 150 Dead

Nine men face prosecution for one of Nigeria's deadliest rural attacks in recent years, as authorities seek to demonstrate action on persistent security crises in the volatile Middle Belt region.

Feb 2, 2026

World

U.S. Envoy Steve Witkoff Heads to Israel for High-Stakes Talks on Iran, Gaza

Senior U.S. envoy Steve Witkoff is set to arrive in Jerusalem for meetings with Prime Minister Netanyahu and military leaders, as Washington seeks to navigate escalating regional tensions with Iran and advance efforts to end the Gaza conflict.

Feb 2, 2026

New Year's Financial Resolutions Already Fading? Five Actionable Steps to Regain Control in 2026

If your 2026 financial goals have already lost momentum, you're not alone. Experts suggest shifting focus to specific, automated strategies and building resilient habits to secure your economic future.

Feb 2, 2026

Business

Cynosure Lutronic's Mosaic 3D Laser Platform Clears Key EU Regulatory Hurdle, Paving Way for Broader Adoption

The European CE Mark under the stringent MDR has been granted for Cynosure Lutronic's innovative fractional resurfacing system, designed to improve safety and patient comfort through advanced cooling and precision technology.

Feb 2, 2026

World

Federal Judge Orders Release of Father and 5-Year-Old Son Detained in ICE Raid, Rebukes Administration

A U.S. federal judge has ordered the release of an Ecuadorian asylum-seeking father and his young son, detained in a Minnesota ICE operation, delivering a scathing critique of the administration's immigration enforcement tactics.

Feb 2, 2026

Business

Is Onto Innovation Fairly Valued? A Deep Dive Into the Semiconductor Metrology Leader's Financial Prospects

A discounted cash flow analysis suggests Onto Innovation's stock is trading close to its intrinsic value. We break down the assumptions behind the model and what it means for investors in the competitive chip equipment sector.

Feb 2, 2026

World

Hungary's Opposition Tisza Holds Steady Lead Over Orban's Fidesz Ahead of Pivotal April Election

A new poll shows the centre-right Tisza party maintaining an eight-point advantage over the ruling Fidesz, setting the stage for Hungary's most consequential vote in over a decade, with major implications for Europe's political landscape.

Feb 2, 2026

Business

Advanced Energy Industries Promoted to S&P 400, Signaling Growth and Shifting Investor Perceptions

Advanced Energy Industries (AEIS) transitions from the S&P 600 to the S&P 400 index, a move that reflects its evolving market stature and is set to alter its visibility among institutional investors and index-tracking funds.

Feb 2, 2026